{'fraction_non_alphanumeric': 0.03115727002967359, 'fraction_numerical': 0.008160237388724036, 'mean_word_length': 5.393364928909953, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
STATINS IN POLYCYSTIC OVARY SYNDROME

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. PCOS varies from a mild menstrual disorder to severe disturbance of reproductive and metabolic functions. Statins, 3-hydroxy-3-methyl-glutarylCoA (HMG-CoA) reductase inhibitors with intrinsic antioxidant properties, exert profound and broad-reaching effects on various types of tissues. By blocking an early step of the mevalonate pathway, statins inhibit proliferation of several cell types including vascular smooth muscles, hepatocytes, and several neoplastic cell lines. The pleiotropic effects of statins may be due to inhibition of cholesterol synthesis. Some common treatments lifestyle changes, insulin-sensitizing agents. INTRODUCTION: Polycystic ovaries are slightly larger than normal ovaries and have twice the number of follicles (small cysts). Polycystic ovaries are very common affecting 20 in 100 (20%) of women. PCOS is a form of hyperandrogenism in which hormonal imbalances cause the ovaries to overproduce androgens. It is a common cause of hirsutism and is frequently associated with irregular or absent ovulation and infertility. In patients with PCOS, multiple small cysts develop in the ovaries, hence the term “poly-cystic (Figure 1). FIG. 1: THE POLYCYSTIC OVARY MAY BECOM ENLARGED WITH MANY SMALL CYSTS